TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02229721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Syntocinon Nasalspray
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon Nasalspray
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasalspray
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Nasalspray
Description: Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.~The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly.
Study: NCT00909025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Claudiximab
Description: Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.~After completion of study treatment, patients are followed for 4 weeks.
Study: NCT04496908

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amniotomy
Description: Artificially rupturing membranes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
Study: NCT04514107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian National Dengue Control Program
Description: This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brazilian National Dengue Control Program
Description: This program has 4 basic principles: 1) Adequate case finding, classification and treatment; 2) Epidemiological surveillance and reporting of all cases; 3) Mobilization and communication of risks to the public; 4) mosquito monitoring and control which consists fundamentally of detection of larva using a rapid larval index (LIRAa) followed by removal of breeding sites and local spraying.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wolbachia-infected Aedes aegypti
Description: Brazilian strain of Aedes aegypti infected with Wolbachia pipientis released into geographic clusters.
Study: NCT02936388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: catheter-based application of radioactive microspheres into the hepatic artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DSM-TACE
Description: catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
Study: NCT02464046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants in arm JNJ-42847922 then Placebo will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2\*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
Study: NCT03598257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary study
Study: NCT04496908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg.
Study: NCT02077777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: Mesalazine cpr 800 mg t.i.d. for 3 months
Study: NCT01798901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC inhibitor AR-42
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02499783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: subcutaneous injections of placebo
Study: NCT02437266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular mobilization
Study: NCT01264900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
Study: NCT02284984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab with belimumab
Description: Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
Study: NCT03131778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: liver resections for colorectal liver metastases

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: liver resections for colorectal liver metastases
Study: NCT00935363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glyburide
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + fluconazole
Description: single dose oral glyburide single dose iv fluconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + rifampin
Description: single dose oral glyburide single dose iv rifampin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glyburide + fluconazole + rifampin
Description: single dose oral glyburide single dose iv fluconazole single dose iv rifampin
Study: NCT02523248

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tonsillectomy
Description: Tonsillectomy with cold steel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatopharyngoplasty
Description: Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
Study: NCT00373152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: gadopentetate dimeglumine
Description: Injected at baseline MRI and post radiofrequency ablation MRI.
Study: NCT02018185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham stimulation of the brain.
Study: NCT01936805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
Study: NCT03050554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
Study: NCT03133182

Intervention type: DRUG
Intervention: Polypharmacy
Description: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery
Study: NCT03050554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
Study: NCT01816204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist assisted online treatment
Description: 7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face individual therapy
Description: weekly individual counseling as usual.
Study: NCT04216849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: human umbilical cord mesenchymal stem cells were peripheral intravenous infused to experimental group
Study: NCT00555971

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Subjects randomized to Omalizumab prior to aspirin desensitization

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects randomized to Placebo prior to aspirin desensitization
Study: NCT01412320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: dissolved in water twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cocoa
Description: dissolved in water twice daily
Study: NCT02667054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RX0041 4%
Description: Anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RX0041 8%
Description: Anesthetic
Study: NCT04216849

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Saline solution containing human serum albumin will be infused to the control group
Study: NCT00512850

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Folic acid
Description: Intervention group 1g folic acid per day
Study: NCT03528772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil
Description: application of minoxidil forte 5% gel three time per day on the anus for four weeks
Study: NCT03150433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral symptom management
Description: Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease

Intervention type: OTHER
Group type: OTHER
Intervention: Sickle cell disease management
Description: Individual sessions focused on understanding and managing sickle cell disease
Study: NCT00512850

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: One placebo pill per day
Study: NCT04644588

Intervention type: DIAGNOSTIC_TEST
Intervention: Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
Description: Children with hemiparetic cerebral palsy being assessed for scapular alignment and upper limb function.
Study: NCT03463473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 3 mg/kg (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 10 mg/kg (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Q3W MSB2311 Injection
Description: An intravenous infusion with concentration from 20 mg/kg (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Q2W MSB2311 Injection
Description: An intravenous infusion with concentration from 10 mg/kg (Q2W)
Study: NCT03967171

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: before uterine incision oxytocin
Description: blood loss during elective cesarean section

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: after clamping the umbilical cord oxytocin
Description: blood loss during elective cesarean section
Study: NCT00332579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study: NCT00862368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAM
Description: Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAM
Description: Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study: NCT03528772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyceryl trinitrate
Description: application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
Study: NCT01008592

Intervention type: DRUG
Intervention: levocetirizine or placebo
Description: oral administration, single tablet, 5 mg.
Study: NCT00862368

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAM
Description: Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAM-Enhanced/Asthma Counseling Phone Calls
Description: PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Phone Calls - Child Wellness Topic
Description: Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
Study: NCT04447235

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Use of the combination of ivermectin plus losartan as early treatment for COVID-19 in cancer patients
Study: NCT01336712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplant
Description: Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.~Fludarabine 30 mg/m\^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4
Study: NCT03520296

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire evaluating well-being in relation to diet and nutrition
Study: NCT01021046

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DALK using GCCT
Description: Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DALK using FCT
Description: Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
Study: NCT02433054

Intervention type: DEVICE
Intervention: CE-certified dedicated venous stents
Description: Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
Study: NCT04271735

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Participants will take two capsules of nicotinamide riboside (NR) by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule to match the active supplement. Participants will take two capsules, twice daily for a total of 4 weeks.
Study: NCT02494180

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: arm A receiving iv fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pethidine
Description: arm B receiving iv pethidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diazepam
Description: arm B receiving iv diazepam

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: arm A receiving iv midazolam